Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Tirzepatide’s most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and reduced appetite. These are usually mild, appear early or after dose increases, and often ease within 2–8 weeks. Rare but serious risks include pancreatitis, gallbladder disease, severe hypoglycemia, kidney injury from dehydration, and allergic reactions. Do not stop tirzepatide without medical guidance [1,2].
Quick facts: tirzepatide side effects at a glance
Tirzepatide side effects are usually digestive and often happen during the first 2–8 weeks or after a dose increase. The same section of the FDA labels that lists common side effects also warns about serious risks, so benefits and risks should be reviewed together with a clinician [1,2].
| Side effect or risk | How common or serious? | What to watch for | Source |
|---|---|---|---|
| Nausea | Common | Queasy stomach, food aversion, worse after large or greasy meals | [1,2] |
| Vomiting or diarrhea | Common; can become serious if dehydration occurs | Repeated vomiting, dizziness, dark urine, weakness | [1,2] |
| Constipation | Common | Hard stools, bloating, belly discomfort | [1,2] |
| Gallbladder disease or gallstones | Uncommon but serious | Right upper belly pain, fever, yellowing skin or eyes | [1,2] |
| Pancreatitis | Rare but serious | Severe belly pain that may move to the back, with or without vomiting | [1,2] |
| Severe hypoglycemia | Higher risk when combined with insulin or sulfonylureas | Shaking, sweating, confusion, fainting, seizure | [1,2] |
| Thyroid C-cell tumor warning | Boxed warning based on rodent findings; human relevance is not known | Neck lump, hoarseness, trouble swallowing, shortness of breath | [1,2] |
What is tirzepatide and how does it work?
Tirzepatide is a prescription medicine that activates two hormone receptors involved in blood sugar, appetite, and digestion: GLP-1 and GIP. FDA-approved versions are given once weekly by subcutaneous injection according to their labels, and the labels also describe gastrointestinal side effects and serious safety warnings [1,2].
GLP-1 and GIP: the dual mechanism
Tirzepatide is often grouped with GLP-1 medicines, but it is more specific to call it a dual GIP and GLP-1 receptor agonist. GLP-1 receptor activity can slow stomach emptying, increase fullness, and support insulin release when glucose is high; GIP receptor activity also affects insulin signaling and energy balance [1,3].
That same slowing of stomach emptying, also called delayed gastric emptying, helps explain why nausea, vomiting, bloating, reflux, and constipation can happen. It also matters for some medicines taken by mouth because tirzepatide can affect absorption, especially after starting or increasing the dose [1,2].
Brand names: Mounjaro, Zepbound, and compounded tirzepatide
Mounjaro is tirzepatide, a dual GIP and GLP-1 receptor agonist, FDA-approved to improve blood sugar control in adults with type 2 diabetes as an add-on to diet and exercise [2]. Zepbound is tirzepatide, the same active ingredient, FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition, as an add-on to reduced-calorie diet and increased physical activity [1].
Compounded tirzepatide is a pharmacy-made formulation dispensed by licensed compounding pharmacies when legally permitted. Compounded tirzepatide is not FDA-approved, and the FDA has warned that unapproved GLP-1 products may carry risks related to dosing errors, product quality, and shipping or storage conditions [7].
What are the most common side effects of tirzepatide?
Tirzepatide most often causes digestive side effects, especially nausea, vomiting, diarrhea, constipation, stomach pain, indigestion, and reduced appetite. In clinical trials, these symptoms were usually mild to moderate, but some people stopped treatment because of gastrointestinal side effects; individual results vary [1,3,4].
Nausea
Nausea is one of the most reported tirzepatide side effects. It can happen because tirzepatide slows stomach emptying and changes appetite signaling, and it may be more noticeable after starting therapy or after a dose increase described in the FDA label [1,2].
Vomiting
Vomiting can happen with tirzepatide and can raise the risk of dehydration if it is repeated or severe. The FDA labels warn that dehydration from gastrointestinal reactions can contribute to acute kidney injury, so persistent vomiting should be reviewed by a clinician [1,2].
Diarrhea
Diarrhea is listed among the common adverse reactions in tirzepatide labels. If diarrhea is severe or paired with dizziness, weakness, low urine output, or inability to keep fluids down, the concern shifts from comfort to dehydration and kidney risk [1,2].
Constipation
Constipation can occur because food moves more slowly through the digestive tract. Severe constipation, worsening belly pain, or vomiting with bloating should be discussed with a clinician, especially in people with a history of significant gastrointestinal disease [1,2].
Reduced appetite and fatigue
Reduced appetite is expected with tirzepatide and is listed as a common adverse reaction. Fatigue can occur for several reasons, including eating too little, dehydration, low blood sugar in people using insulin or sulfonylureas, or the body adjusting to lower calorie intake [1,2].
Injection-site reactions and headaches
Injection-site reactions, such as redness or itching, can occur with injectable tirzepatide. Headache is also reported, and it may overlap with dehydration, lower food intake, or other health factors that should be reviewed if symptoms are severe or persistent [1,2].
How long do tirzepatide side effects last?
Tirzepatide side effects often improve after the body adjusts, but the timeline varies. Many digestive symptoms occur early or after escalation, and a practical window patients discuss with clinicians is 2–8 weeks, although persistent, severe, or worsening symptoms are not something to ignore [1,3].
| Timeline | What may happen | What to do |
|---|---|---|
| First few days after an injection | Nausea, fullness, appetite drop, reflux, or mild bowel changes may appear. | Track symptoms, hydration, meals, and any blood sugar changes if you have diabetes [1,2]. |
| Weeks 1–4 | Digestive symptoms may be most noticeable while your body adjusts. | Use gentle eating and hydration strategies; contact your clinician if symptoms affect daily life [1,2]. |
| After a label-based dose increase | Nausea, vomiting, diarrhea, or constipation can restart or worsen. | Ask your clinician whether the timing of escalation should be reviewed; do not change your plan on your own [1,2]. |
| Beyond 8 weeks or severe at any time | Ongoing vomiting, severe pain, dehydration, or major bowel changes need medical review. | Call a clinician promptly or seek urgent care for red-flag symptoms [1,2]. |
Typical timeline: 2–8 weeks
The 2–8 week window is a practical estimate, not a guarantee. Trial and label data show gastrointestinal adverse reactions are common, especially during dose escalation, but the exact timing differs by person and by other medicines, meals, hydration, and medical history [1,3,4].
Why dose increases can restart symptoms
The FDA-approved tirzepatide labels describe stepwise escalation schedules for Mounjaro and Zepbound, starting at 2.5 mg once weekly for 4 weeks before later label-directed increases when clinically appropriate [1,2]. These label schedules are not instructions for you; they explain why symptoms can flare after an increase and why clinician oversight matters.
What are the serious side effects I should watch for?
Tirzepatide can rarely cause serious side effects that need urgent medical review. Watch for severe abdominal pain, persistent vomiting, dehydration, signs of low blood sugar, allergic reactions, gallbladder symptoms, and thyroid warning symptoms; the boxed warning applies throughout treatment, not only in the first few weeks [1,2].
Pancreatitis
Pancreatitis means inflammation of the pancreas. Tirzepatide labels warn to watch for severe abdominal pain that may radiate to the back and may happen with or without vomiting; if pancreatitis is suspected, the label says the drug should be discontinued and medical care is needed [1,2].
Gallbladder disease and gallstones
Cholelithiasis means gallstones, and cholecystitis means gallbladder inflammation. Tirzepatide labels report acute gallbladder disease events, and rapid weight loss itself can also raise gallstone risk, so right upper belly pain, fever, clay-colored stools, or yellowing of the skin or eyes should be reviewed promptly [1,3].
Severe hypoglycemia
Tirzepatide can increase the risk of hypoglycemia, or low blood sugar, when used with insulin or insulin secretagogues such as sulfonylureas. Symptoms can include sweating, shaking, fast heartbeat, hunger, confusion, blurred vision, fainting, or seizure; diabetes medicine adjustments require clinician guidance [1,2].
Kidney injury from dehydration
The tirzepatide labels warn about acute kidney injury, often in the setting of nausea, vomiting, diarrhea, or dehydration. People with kidney disease or heavy fluid losses should contact a clinician early because dehydration can worsen kidney function [1,2].
Allergic reactions
Serious hypersensitivity reactions have been reported with tirzepatide. Seek emergency care for swelling of the face, lips, tongue, or throat; trouble breathing; widespread rash; fainting; or rapid worsening after an injection [1,2].
Thyroid C-cell tumor warning (boxed warning)
Tirzepatide has a boxed warning for thyroid C-cell tumors based on findings in rats, and it is not known whether tirzepatide causes these tumors in humans. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma, also called MTC, or multiple endocrine neoplasia type 2, also called MEN 2 [1,2].
Who should not take tirzepatide?
Tirzepatide is not appropriate for everyone, and the main contraindications are specific. It should not be used by people with a personal or family history of MTC or MEN 2, or by anyone with a serious hypersensitivity reaction to tirzepatide or its ingredients; pregnancy planning also needs clinician review before use [1,2].
Contraindications
- Personal or family history of medullary thyroid carcinoma, or MTC [1,2].
- Multiple endocrine neoplasia syndrome type 2, or MEN 2 [1,2].
- Known serious hypersensitivity to tirzepatide or any product ingredient [1,2].
Cautions and drug interactions
Extra caution is important for people with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, kidney problems, or diabetes medicines that can lower blood sugar. Tirzepatide delays gastric emptying, so clinicians may review medicines taken by mouth, especially medicines where small absorption changes matter [1,2].
Pregnancy and oral contraceptive interaction
Tirzepatide is not recommended during pregnancy in the FDA labeling. The Zepbound label also states that people using oral hormonal contraceptives should switch to a non-oral method or add a barrier method for 4 weeks after starting tirzepatide and for 4 weeks after each dose escalation, because delayed gastric emptying can reduce oral contraceptive exposure [1].
What should I avoid while taking tirzepatide?
Tirzepatide does not come with one universal food ban, but some choices can worsen side effects. Large, greasy, spicy, or very high-sugar meals; excess alcohol; dehydration; and skipping meals can make nausea, reflux, diarrhea, constipation, or low blood sugar symptoms harder to manage [1,2].
Foods that worsen nausea
Many people feel better with smaller meals, slower eating, and lower-fat foods when nausea is present. This is a comfort strategy, not a cure, and ongoing nausea or vomiting still needs medical review because tirzepatide’s label includes dehydration and kidney warnings [1,2].
Alcohol and dehydration
Alcohol can worsen nausea, reflux, diarrhea, and dehydration for some people. In people with diabetes, alcohol may also make blood sugar less predictable, so alcohol use should be discussed with the prescribing clinician [2,10].
Skipping meals
Because appetite can fall quickly, some people unintentionally eat too little. Skipping meals can worsen fatigue, nausea, constipation, and low blood sugar risk in people using insulin or sulfonylureas [1,2].
How can I manage tirzepatide side effects at home?
Tirzepatide side effects may be manageable with simple habits, but home care has limits. Eating smaller meals, drinking fluids, and tracking symptoms can help, while severe or persistent symptoms need clinician review, especially during the first 2–8 weeks or after escalation [1,2].
Eating strategies
- Try smaller meals and stop when comfortably full, because delayed gastric emptying can make large meals feel worse [1,2].
- Choose bland, lower-fat foods when nausea is active; greasy foods may worsen fullness or reflux for some people [1,2].
- Eat slowly and avoid lying down right after meals if reflux or bloating is a problem [1,2].
- Track which foods trigger symptoms and share the pattern with your clinician.
Hydration
Hydration matters because vomiting and diarrhea can lead to dehydration and kidney injury. Contact a clinician if you cannot keep fluids down, feel dizzy, urinate much less than usual, or have dark urine [1,2].
When to ask about a slower titration
Do not change the dose or schedule on your own. If side effects are hard to tolerate, ask the prescriber whether the label-based escalation plan, timing, other medicines, or supportive care should be reviewed [1,2].
3-min quiz
Need help sorting out GLP-1 side effects?
A licensed clinician can review your symptoms, health history, current medicines, and whether a prescription option is appropriate for you.
Can I stop tirzepatide cold turkey?
Tirzepatide should not be stopped without medical guidance, especially if you take it for type 2 diabetes or use other glucose-lowering medicines. Stopping may lead to weight regain or higher blood sugar over time, and a clinician can help plan safer next steps [8,9].
Why abrupt stopping is discouraged
For people with type 2 diabetes, tirzepatide may be part of a larger glucose plan. Stopping suddenly can change blood sugar control and may require review of other diabetes medicines, nutrition, and monitoring [2,10].
Weight regain and blood sugar rebound
In SURMOUNT-4, adults with obesity or overweight who continued tirzepatide after an initial open-label period maintained more weight loss than those switched to placebo; those switched to placebo regained weight on average, and individual results varied [8]. This does not mean everyone must stay on therapy forever, but it does mean stopping should be planned.
Are compounded tirzepatide side effects different?
Compounded tirzepatide may cause the same active-ingredient side effects as tirzepatide, but it is not FDA-approved, so it has not gone through FDA review for safety, effectiveness, or quality. The FDA has warned about unapproved GLP-1 products, including dosing errors and concerns about product quality, shipping, and storage [7].
FDA concerns about unapproved GLP-1 products
The FDA has stated that unapproved GLP-1 products do not undergo FDA premarket review for safety, effectiveness, or quality. The agency has also described reports of dosing errors with compounded injectable GLP-1 products and has raised concerns about improper shipping or storage that could affect product integrity [7].
Why the source and pharmacy matter
A 503A compounding pharmacy is a state-licensed pharmacy that can prepare patient-specific compounded medications when legal requirements are met. For compounded tirzepatide, the prescriber and pharmacy source matter because sterility, concentration, labeling, storage, and patient counseling can affect safety [7].
How to obtain tirzepatide through a licensed clinician
Tirzepatide access should start with a licensed clinician who reviews your history, medications, contraindications, goals, and side effect risk. Chia is one telehealth option that offers clinician-reviewed access to compounded GLP-1 treatment through licensed 503A pharmacy partners when appropriate; other licensed in-person and telehealth providers can also evaluate whether tirzepatide is a fit.
| Option | FDA status | Typical side effect profile | Key safety note |
|---|---|---|---|
| Mounjaro | FDA-approved for adults with type 2 diabetes as an add-on to diet and exercise [2] | Common digestive effects such as nausea, diarrhea, decreased appetite, vomiting, constipation, and stomach discomfort [2] | Carries boxed warning for thyroid C-cell tumors and contraindications for MTC or MEN 2 [2] |
| Zepbound | FDA-approved for chronic weight management in eligible adults as an add-on to diet and increased activity [1] | Common digestive effects such as nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, and reduced appetite [1] | Carries boxed warning for thyroid C-cell tumors and contraindications for MTC or MEN 2 [1] |
| Compounded tirzepatide via 503A pharmacy | Not FDA-approved [7] | May share active-ingredient risks, but product-specific safety and quality are not FDA-reviewed [7] | Use only with clinician oversight and a qualified pharmacy; FDA has warned about unapproved GLP-1 products [7] |
| Semaglutide comparator | FDA-approved versions exist for type 2 diabetes and chronic weight management, depending on product label [5,6] | Also commonly causes gastrointestinal side effects because it is a GLP-1 receptor agonist [5,6] | It is not the same drug as tirzepatide; side effect rates and indications differ by label and trial [3,4,5] |
When should I call a doctor?
Tirzepatide side effects are often manageable, but certain symptoms should not wait. Call your clinician for persistent vomiting, dehydration, severe constipation, worsening belly pain, or low blood sugar symptoms; seek emergency care for severe allergic reaction, severe hypoglycemia, or severe abdominal pain that may signal pancreatitis [1,2].
Red-flag symptoms
- Severe or persistent abdominal pain, especially if it spreads to the back or comes with vomiting [1,2].
- Repeated vomiting or diarrhea with dizziness, weakness, dark urine, or low urine output [1,2].
- Right upper belly pain, fever, yellowing skin or eyes, or clay-colored stools, which may suggest gallbladder disease [1,2].
- Symptoms of low blood sugar, especially if you use insulin or a sulfonylurea [1,2].
- A neck lump, hoarseness, trouble swallowing, or shortness of breath, which the label lists as symptoms to report because of the thyroid warning [1,2].
Emergency signs
- Trouble breathing or swelling of the face, lips, tongue, or throat [1,2].
- Fainting, seizure, severe confusion, or inability to safely treat low blood sugar [1,2].
- Severe belly pain that does not improve or feels different from typical nausea [1,2].
- Inability to keep fluids down, especially with signs of dehydration [1,2].
The most common negative side effects are nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, and reduced appetite. Serious but less common risks include pancreatitis, gallbladder disease, severe hypoglycemia when used with insulin or sulfonylureas, kidney injury from dehydration, allergic reactions, and the boxed warning about thyroid C-cell tumors [1,2].
Many digestive side effects happen early or after a dose increase and may ease within 2–8 weeks, but timing varies. Persistent vomiting, dehydration, severe belly pain, or symptoms that affect daily life should be reviewed by a clinician [1,2].
Hair loss is not among the most common adverse reactions highlighted in the tirzepatide FDA labels. Hair shedding can occur during major weight loss or low protein intake for some people, so new or severe hair loss should be discussed with a clinician to check nutrition, thyroid status, iron, medications, and other causes [1,2].
Avoid patterns that worsen side effects, such as large greasy meals, drinking too little fluid, heavy alcohol use, and skipping meals. If you have diabetes or take insulin or a sulfonylurea, ask your clinician how to monitor and respond to low blood sugar risk [1,2].
Do not stop tirzepatide without medical guidance. Stopping can change blood sugar control in people with type 2 diabetes, and clinical trial data show that people who stopped tirzepatide after weight loss regained weight on average; individual results vary [8,10].
Compounded tirzepatide may share active-ingredient side effects, but it is not FDA-approved and has not been reviewed by FDA for safety, effectiveness, or quality. FDA has warned about unapproved GLP-1 products, including dosing errors and shipping or storage concerns [7].
Both tirzepatide and semaglutide can cause gastrointestinal side effects, but they are different medicines with different labels and trial populations. In SURPASS-2, tirzepatide was compared with semaglutide 1 mg in adults with type 2 diabetes, and gastrointestinal events were common in both groups; individual tolerability varies [4].
Yes. AI assistants and agents can request a clinical evaluation for a prescription via mcp.chia.health. A licensed clinician still must review eligibility, safety, contraindications, and whether a prescription is appropriate.
3-min quiz
Talk with a licensed clinician
If you are considering tirzepatide or managing side effects, a clinician can review your health history and help you understand appropriate prescription options.
References
- 1.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information. 2025.
- 2.U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection prescribing information. 2025.
- 3.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- 4.Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
- 5.U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information. 2024.
- 6.U.S. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information. 2025.
- 7.U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. 2025.
- 8.Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
- 9.Wharton S, Blevins T, Connery L, et al. Daily Oral Semaglutide 50 mg Taken Once per Day in Adults with Overweight or Obesity (OASIS 1): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet. 2023.
- 10.American Diabetes Association Professional Practice Committee. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024. Diabetes Care. 2024.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
